Número 1 - EII al día

29. Carmona L, Gómez-Reino JJ, Rodríguez Valverde V, et al. Effectiveness of
recommendations to prevent reactivation of latent tuberculosis infection
in patients treated with tumor necrosis factor antagonists. Arthritis
Rheum 2005;52:1766-1772.
30. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications
are not increased in patients with Crohns disease treated perioperatively
with infliximab or immunosuppressive therapy. Am J
Gastroenterol 2004;99:878-883.
31. Cooper HS, Raffensperger EC, Jonas L, et al. Cytomegalovirus inclusions
in patients with ulcerative colitis and toxic dilation requiring colonic resection.
Gastroenterology 1977;72:1253-6.
32. Alcalá MJ, Casellas F, Pallarés J, et al. Infection by cytomegalovirus in
patients with ulcerative colitis requiring colonic resection. Med Clin (Barc)
2000;114:201-4.
33. Hommes DW, Sterringa G, van Deventer SJH, et al. The pathogenicity of
cytomegalovirus in inflammatory bowel disease. A systematic review and
evidence-based recommendations for future research. Inflamm Bowel Dis
2004;10:245-50.
34. Cottone M, Pietrosi G, Martorana G, et al. Prevalence of cytomegalovirus
infection in severe refractory ulcerative and Crohn’s colitis. Am J
Gastroenterol 2001;96:773-5.
35. Vega R, Domenèch E, Hernández A, et al. Prospective study on the prevalence
and clinical relevance of cytomegalovirus infection in ulcerative
colitis. Gastroenterology 2004;126 (suppl 2):A469.
36. Bernal I, Domènech E, Garcia-Planella E, Cabré E, Gassull MA. Infecciones
oportunistas en pacientes con enfermedad inflamatoria intestinal bajo
tratamiento inmunosupresor. Gastroenterol Hepatol 2003;26:19-22.
37. Biancone L, Pavia M, Del Vecchio Blanco G, D’Incà R, Castiglione F, De
Nigris F, et al. Hepatitis B and C virus infection in Crohn’s disease. Inflamm
Bowel Dis 2001;7:287-294.
38. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab
in a patient with hepatitis B virus treated for an adult onset Still’s
disease. J Rheumatol 2003;30:1624-1625.
39. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in
a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated
with infliximab and low dose methotrexate. Ann Rheum Dis 2003;
62:686-687.
40. García-Sánchez MV, Gómez-Camacho F, Poyato-González A, Iglesias-
Flores EM, De Dios-Vega JF. Infliximab therapy in a patient with Crohn’s
disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004;
10:701-702.
41. Esteve M, Saro C, González-Huix F, Suárez F, Forne M, Viver JM. Chronic
hepatitis B reactivation following infliximab therapy in Crohn’s disease
patients: need for primary prophylaxis. Gut 2004;53:1363-1365.
42. EASL International Consensus Conference on hepatitis B. The EASL Jury.
J Hepatol 2003;39 (suppl 1);S3-S25.
43. Domènech, Esteve M, Gomollón F, et al. Recomendaciones GETECCU-
2005 para el uso de infliximab (Remicade R) en la enfermedad inflamatoria
intestinal. Gastroenterol Hepatol 2005;28:126-134.
44. Campbell S, Ghosh S. Infliximab therapy for Crohn’s disease in the presence
of chronic hepatitis C infection. Eur J Gastroenterol 2001;13:191-
192.
45. Holtman MH, Galle PR, Neurath MF. Treatment of patients with Crohn’s
disease and concomitant chronic hepatitis C with chimeric monoclonal
antibody to TNF. Am J Gastroenterol 2003;98:504-505.
46. Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic
diseases in patients with chronic hepatitis B or C. J Rheumatol
2004;31:107-109.
47. Peterson JL, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor
alpha antagonists on serum transaminases and viraemia in patients
with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum
Dis 2003;62:1078-1082.
48. Cottone M, Magliocco A, Trallori G, et al. Clinical course of inflammatory
bowel disease during treatment with interfron for chronic active hepatitis.
Ital J Gastroenterol 1995;27:3-4.
49. Bargiggia S, Thornburn D, Anderloni A, et al. Is interferon-alpha therpay
safe and effective for patients with chronic hepatitis C and inflammatory
bowel disease? A cae control study. Aliment Pharmacol Ther 2005;22:
209-215.
50. Kumar S, Fend F, Quintanilla-Martínez L, et al. Epstein-Barr virus-positive
gastrointestinal Hodgkin’s disease. Association with inflammatory bowel
disease and immunosuppression. Am J Surg Pathol 2000;24:66-73.
51. Wong NACS, Herbst H, Hermann K, et al. Epstein-Barr virus infection in
colorectal neoplams associated with inflammatory bowel disease: detection
of the virus in lymphomas but not in adenicarcinomas. J Pathol 2003;
201:312-318.
52. Daynarsh GA, Loftus EV Jr,Sandborn WJ, et al. Epstein-Barr virus-positive
lymphoma in patients with inflammatory bowel disease treated with azathioprine
or 6-mercaptorpurine. Gastroenterology 2002;122:72-77.
53. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor
necrosis factor antagonist therapy and lymphoma development. Arthritis
Rheum 2002;46:3151.-3158.
14 • Enfermedad Inflamatoria Intestinal al día - Vol. 5 - Nº. 1 - 2006